Raynaud Clinical Trial
Official title:
Tadalafil for the Treatment of Secondary Raynaud's Phenomenon
The investigators propose that tadalafil will increase digital blood flow and improve the symptoms and signs of secondary Raynaud's phenomenon.
The primary goal of our study is to decrease the frequency, duration and severity of vasospastic attacks in patients with secondary Raynaud's. The secondary goal is to document increased blood flow and lessened capillary dysfunction in these patients. Both of these goals are to be achieved using a course of treatment with Tadalafil.We anticipate a decrease in the frequency, duration and severity of Raynaud's attacks. Improved digital blood flow and digital blood pressures, and a decrease in digital capillary dysfunction. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03941184 -
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
|
||
| Completed |
NCT00498615 -
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
|
Phase 3 |